2 valid isoforms with distinct clinical profile · MK-4 high-dose bone evidence · MK-7 low-dose long half-life cardiovascular · combo possible for complete protocol.
All-trans MK-4 · natural form
Best for
Ideal use: confirmed osteoporosis, postmenopausal low T-score, family fracture profile.
Advantages
Human endogenous form · robust high-dose bone evidence (Sato 2024 RCT). Dose-dependent Gla-OC and MGP activation. Classic Japan osteoporosis pathway approved Glakay®.
Disadvantages
Short half-life 1h · requires 2-3 doses/day (inconvenient). Expensive at high doses 45 mg/d (~30-50 €/month).
All-trans MK-7 from natto (Nattopharma MenaQ7®)
Best for
Ideal use: general longevity prevention, CV maintenance, early postmenopausal without fracture.
Advantages
Half-life ~3 days · single dose/day. Economical (~10-25 €/month at 100-200 mcg). Cardiovascular and preventive bone evidence. More practical stack.
Disadvantages
High doses 1+ mg/d expensive · bone fracture evidence not as robust as high-dose MK-4.
Hybrid dosing stack
Best for
Ideal use: postmenopausal with osteoporosis + CV calcification profile. Complete pro protocol.
Advantages
Short + long half-life coverage. Maximum 24h sustained Gla activation. Pro 2026 protocol postmenopausal pro.
Disadvantages
Expensive (~50+ €/month). Greater logistic complexity (2-3 doses/d + 1 dose/d).
Ideal use: confirmed osteoporosis, postmenopausal low T-score, family fracture profile.
Ideal use: general longevity prevention, CV maintenance, early postmenopausal without fracture.
Ideal use: postmenopausal with osteoporosis + CV calcification profile. Complete pro protocol.
2 valid isoforms with distinct clinical profile · MK-4 high-dose bone evidence · MK-7 low-dose long half-life cardiovascular · combo possible for complete protocol.